Undervalued Drug Manufacturer Stocks on NYS October 2024

October 19, 2024

Drug Manufacturers

Drug Manufacturers are engaged in pharmaceutical manufacturing or sale of a diverse line of drug and healthcare products. This industry group also includes companies engaged in the development and discovery of new dugs, and tobacco and cannabis companies.

New York Stock Exchange

The New York Stock Exchange, located in New York City, is the largest securities exchange in the world by market capitalization of its listed companies.

Our Valuation

A stock is considered undervalued if it trades at a discount to our valuation. To determine a stock’s intrinsic value, we developed an algorithm that uses 6 valuation models to determine the value of a company.* To learn more about stockcalc’s valuation methods, click here.

Undervalued Drug Manufacturers stocks

Stocks in this category are held primarily for potential income and capital appreciation.

For an in-depth look at the fundamentals and valuation of each company, try the stockcalc platform free for 30 days.

SymbolNameClose Price ($)Valuation ($)Difference (%)Average Vol (30D)Market Cap ($M)Yield (%)P/E Ratio
ELAN Elanco Animal Health 12.97 26.07 100.98 5259672 6410 0.00 0.0
CTLT Catalent 60.29 71.40 18.42 1576554 10912 0.00 0.0
OGN Organon 17.61 20.74 17.78 2185023 4554 6.36 4.5
GSK GSK 38.55 44.76 16.10 5232433 79452 3.97 13.2
ZTS Zoetis 193.28 211.22 9.28 1721064 88136 0.86 37.9
NVS Novartis 117.18 127.29 8.63 912432 239750 3.22 24.0
RDY Dr Reddy's Laboratories 79.67 82.50 3.56 159289 13288 0.60 20.1
PFE Pfizer 29.22 29.97 2.57 30311496 166437 5.72 0.0
All data provided as at market close October 17, 2024.

Company Details

Elanco Animal Health

ELAN:NYS

Close Price

12.97

Our Valuation

26.07

% Difference

100.98

Market Cap ($M)

6410

P/E Ratio

0.0

Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries.

Access the stockcalc valuation


Catalent

CTLT:NYS

Close Price

60.29

Our Valuation

71.40

% Difference

18.42

Market Cap ($M)

10912

P/E Ratio

0.0

Catalent is a contract development and manufacturing organization, or CDMO. It operates under four segments: biologics, softgel and oral technologies, oral and specialty delivery, and clinical supply services. Catalent derives its revenues primarily from long-term supply agreements with pharmaceutical customers.

Access the stockcalc valuation


Organon

OGN:NYS

Close Price

17.61

Our Valuation

20.74

% Difference

17.78

Market Cap ($M)

4554

P/E Ratio

4.5

Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars, and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan.

Access the stockcalc valuation


GSK

GSK:NYS

Close Price

38.55

Our Valuation

44.76

% Difference

16.10

Market Cap ($M)

79452

P/E Ratio

13.2

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, antiviral, and vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.

Access the stockcalc valuation


Access our valuation for these companies and 9,000+ more

Try the stockcalc platform free for 30 days

Sign Up

Zoetis

ZTS:NYS

Close Price

193.28

Our Valuation

211.22

% Difference

9.28

Market Cap ($M)

88136

P/E Ratio

37.9

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its us business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals.

Access the stockcalc valuation


Novartis

NVS:NYS

Close Price

117.18

Our Valuation

127.29

% Difference

8.63

Market Cap ($M)

239750

P/E Ratio

24.0

Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.

Access the stockcalc valuation


Dr Reddy's Laboratories

RDY:NYS

Close Price

79.67

Our Valuation

82.50

% Difference

3.56

Market Cap ($M)

13288

P/E Ratio

20.1

Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr.

Access the stockcalc valuation


Pfizer

PFE:NYS

Close Price

29.22

Our Valuation

29.97

% Difference

2.57

Market Cap ($M)

166437

P/E Ratio

0.0

Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis.

Access the stockcalc valuation


Access thousands of valuation reports

Try the stockcalc platform for 30 days for unlimited access to our valuation reports

Sign Up
Elanco Animal Health and Catalent are the most undervalued Drug Manufacturers stocks on the NYS. See the full list on the blog: https://www.stockcalc.com/Blog/undervalued-drug-manufacturer-stocks-nys-october-2024
Elanco Animal Health $ELAN and Catalent $CTLT are the most undervalued Drug Manufacturers stocks on the #NYS. See the full list: https://www.stockcalc.com/Blog/undervalued-drug-manufacturer-stocks-nys-october-2024
Elanco Animal Health and Catalent are the most undervalued Drug Manufacturers stocks on the NYS. See the full list on the blog: https://www.stockcalc.com/Blog/undervalued-drug-manufacturer-stocks-nys-october-2024

Copyright © 2016- Patchell Brook Equity Analytics Inc. All rights reserved.

Risk Disclosure: Equities trading and trading of all markets, exchanges and instruments contains substantial risk and is not for every investor. An investor could potentially lose all or more than the initial investment. Risk capital is money that can be lost without jeopardizing ones’ financial security or life style. Only risk capital should be used for trading and only those with sufficient risk capital should consider trading. Past performance is not necessarily indicative of future results. View full risk information here.